BioNTech SE

Our vision: Harnessing the immune system’s power to turn science into survival.
Data Privacy:

[BioNTech SE @BioNTech_Group]

Read more 🔗: https://t.co/qgwejJFMUy

[BioNTech SE @BioNTech_Group]

🎗 Not every breast cancer journey looks the same.

For people living with metastatic breast cancer, treatment can become part of everyday life and options may change over time.

Here are 5 reasons why continued research matters, during #BreastCancerAwarenessMonth and every day.

[BioNTech SE @BioNTech_Group]

Lung cancer is not one disease.

Following #WCLC26, Dr.@StephenVLiu reflects on the complexity of lung cancer, how our understanding has evolved and why different strategies need to be explored to address the needs that remain.

Watch 👇

#LungCancer #CancerResearch

[BioNTech SE @BioNTech_Group]

📢 Oncology news in 2L+ sqNSCLC: We presented the first median overall survival data from the PRESERVE-003 Phase 3 trial for a chemotherapy-free CTLA-4-targeting immunotherapy in 2L+ squamous non-small cell lung cancer.
🔗 Learn more: https://t.co/pRJObzsXtr
#LungCancer #WCLC26

[BioNTech SE @BioNTech_Group]

We are excited to share new clinical data from our diversified lung cancer pipeline, including the first combination data for any PD-(L)1xVEGF bispecific plus a B7H3 ADC in lung cancer.

🔗 Learn more: https://t.co/wi0RxnC3Cb

#LungCancer #Oncology #WCLC26 #BioNTech

[BioNTech SE @BioNTech_Group]

Photo copyright Guido Oelkers: Sobi - Swedish Orphan Biovitrum AB (publ), 2026

[BioNTech SE @BioNTech_Group]

📢 𝗤𝟮 𝟮𝟬𝟮𝟲 𝗲𝗮𝗿𝗻𝗶𝗻𝗴𝘀 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗮𝗻𝗱 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝘂𝗽𝗱𝗮𝘁𝗲

𝗟𝗶𝗻𝗸 𝘁𝗼 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀:

https://t.co/Vuzq8yVvGD

[BioNTech SE @BioNTech_Group]

We are building for the many within lung cancer. Through 16+ clinical trials, we are pursuing innovative therapeutic approaches across subtypes and biomarkers to advance progress where patients still need more.

Explore the many: https://t.co/Zyfprgjp9U

#WorldLungCancerDay

[BioNTech SE @BioNTech_Group]

At #ASCO26, we presented interim data from the global Phase 2/3 ROSETTA Lung-02 clinical trial evaluating an investigational PD-L1 x VEGF-A bispecific immunomodulator in 1L squamous and non-squamous #NSCLC.

[BioNTech SE @BioNTech_Group]

At #SGOAM26 we are presenting data from the largest trial to date to report results for a HER2-targeted ADC in recurrent HER2-expressing endometrial cancer.
Read more: https://t.co/UHMZfMotjm

#BioNTech #WomensCancer #GynecologicOncology

[BioNTech SE @BioNTech_Group]

The candidate is being developed by BioNTech and OncoC4.

Join the proffered paper session at 3:35 pm CET in Auditorium A1.

[BioNTech SE @BioNTech_Group]

Tomorrow at #ELCC26, Dr. Kai He will share data from stage 1 of the global Phase 3 PRESERVE-003 clinical trial evaluating a tumor microenvironment-selective regulatory T cell depletion candidate targeting CTLA-4 in second-line or later therapy of squamous NSCLC.

[BioNTech SE @BioNTech_Group]

Join the poster session at 1:00 pm CET in the Foyer.

[BioNTech SE @BioNTech_Group]

Tomorrow at #ELCC26, @bensolomon1 will share the global Phase 2/3 ROSETTA Lung-02 trial design evaluating a PD-L1xVEGF-A bispecific immunomodulator plus chemotherapy in first-line non-small cell lung cancer (NSCLC).The candidate is being developed by BioNTech and @bmsnews

[BioNTech SE @BioNTech_Group]

At the #ELCC2026, we will present new clinical data from our late-stage portfolio across various #lungcancer subtypes and lines of treatment, reinforcing the transformative potential of our treatment approaches in this critical area.

👉https://t.co/zHKIDyC983

#nsclc #esclc